First-line chemotherapy plus immune checkpoint inhibitors or bevacizumab in advanced non-squamous non-small-cell lung cancer without EGFR mutations or ALK fusions.
- Resource Type
- Article
- Source
- Immunotherapy (1750743X); Apr2022, Vol. 14 Issue 6, p445-457, 13p
- Subject
- Language
- ISSN
- 1750743X